Form 4: Immunocore Holdings Director Acquires Share Options
SEC Form 4
Director John Irving Bell acquired share options in Immunocore Holdings plc on May 15, 2025.
Summary
- On May 15, 2025, John Irving Bell, a director of Immunocore Holdings plc, acquired 26,198 share options.
- The exercise price of these options is $29.06.
- The options vest at the earlier of May 15, 2026, or the day before the next annual general meeting, contingent upon continuous service.
- The options expire on May 14, 2035.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of share options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- Shareholders are informed about the director's acquisition of share options, providing transparency into insider activity.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of transaction: Director acquired share options. |
| 05/15/2026 | Earliest vesting date for the share options. |
| 05/14/2035 | Expiration date of the share options. |
Keywords
Immunocore Holdings, share options, director, acquisition, IMCR, Bell, John Irving Bell
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.